Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 18/20 | 0.83 |
| ▸ | BCR | P11274 | 9/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.83 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.83 |
| ▸ | KIT | P10721 | 7/20 | 0.83 |
| ▸ | LCK | P06239 | 4/20 | 0.83 |
| ▸ | LYN | P07948 | 4/20 | 0.83 |
| ▸ | FLT3 | P36888 | 4/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.83 |
| ▸ | LDLR | P01130 | 2/20 | 0.83 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.83 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.83 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.83 |
| ▸ | CA12 | O43570 | 1/20 | 0.83 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.83 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.83 |
| ▸ | STK10 | O94804 | 1/20 | 0.83 |
| ▸ | CA1 | P00915 | 1/20 | 0.83 |
| ▸ | CA2 | P00918 | 1/20 | 0.83 |
| ▸ | RAF1 | P04049 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31017569 | 1.00 | ABL1 (0.83) | ABL1BCRPDGFRAPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL28636000 | 0.99 | ABL1 (0.82) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL22169874 | 0.94 | ABL1 (0.81) | ABL1BCRPDGFRAPDGFRBKIT | |
| SCHEMBL3533748 | 0.92 | ABL1 (0.70) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL29366964 | 0.91 | ABL1 (1.00) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL29580067 | 0.91 | ABL1 (1.00) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL7901 | 0.91 | ABL1 (1.00) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL9990634 | 0.90 | ABL1 (0.99) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL1984397 | 0.90 | ABL1 (0.99) | ABL1BCRPDGFRAPDGFRBKIT | |
| Nilotinib SCHEMBL434496 | 0.90 | ABL1 (0.99) | ABL1BCRPDGFRAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | claimed |
| EP-3877379-A1 | CRYSTALLINE FORM OF NILOTINIB HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Laurus Labs Limited (IN) | 2021-09-15 | — | — | EP | disclosed |
| CN-111329863-A | Use of a composition containing a heterocyclic compound for the preparation of a medicament for the treatment of leukemia | 黄泳华 | 2020-06-26 | — | — | CN | disclosed |
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS GROUP, INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, IL5 | ABL1 372/4885BCR 1625/4885PDGFRA 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.